
Sign up to save your podcasts
Or


The paper details a scientific study identifying a progenitor-like cell state that serves as a critical intermediate during the development of pancreatic ductal adenocarcinoma (PDAC). These high-plasticity cells emerge following tissue injury and oncogenic KRAS activation, forming a self-reinforcing cancer-like niche that mimics the malignant environment. Research shows that this state is a site of intense conflict between tumor-promoting mutations and suppressive forces like p53, which normally works to dismantle these niches and restore tissue balance. By using mouse models and human tissue analysis, the authors demonstrate that p53 loss allows these progenitor cells to expand and transition into invasive cancer. Conversely, the study highlights a therapeutic opportunity, as inhibiting KRAS or maintaining p53 activity collapses the niche and delays the onset of malignancy. Ultimately, these findings position the progenitor niche as a vital target for intercepting pancreatic cancer at its earliest stages.
References:
Reyes J, Del Priore I, Chaikovsky A C, et al. Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition[J]. Cell, 2025.
By 淼淼ElvaThe paper details a scientific study identifying a progenitor-like cell state that serves as a critical intermediate during the development of pancreatic ductal adenocarcinoma (PDAC). These high-plasticity cells emerge following tissue injury and oncogenic KRAS activation, forming a self-reinforcing cancer-like niche that mimics the malignant environment. Research shows that this state is a site of intense conflict between tumor-promoting mutations and suppressive forces like p53, which normally works to dismantle these niches and restore tissue balance. By using mouse models and human tissue analysis, the authors demonstrate that p53 loss allows these progenitor cells to expand and transition into invasive cancer. Conversely, the study highlights a therapeutic opportunity, as inhibiting KRAS or maintaining p53 activity collapses the niche and delays the onset of malignancy. Ultimately, these findings position the progenitor niche as a vital target for intercepting pancreatic cancer at its earliest stages.
References:
Reyes J, Del Priore I, Chaikovsky A C, et al. Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition[J]. Cell, 2025.